Skip to main content
Orum Therapeutics, Inc. logo

Orum Therapeutics, Inc. — Investor Relations & Filings

Ticker · 475830 ISIN · KR7475830006 KO Professional, scientific and technical activities
Open in API
Filings indexed 84 across all filing types
Latest filing 2026-03-05 Regulatory Filings
Country KR South Korea
Listing KO 475830

About Orum Therapeutics, Inc.

https://www.orumrx.com/

Orum Therapeutics is a clinical-stage biotechnology company that develops targeted protein degradation (TPD) therapeutics. The company's proprietary TPD²® platform creates a novel class of antibody-drug conjugates (ADCs), referred to as degrader-antibody conjugates (DACs). This technology combines the cell-targeting precision of antibodies with the catalytic action of protein degraders. The approach is designed to selectively deliver payloads to diseased cells to eliminate intracellular proteins that are difficult to target with conventional drugs. Orum's primary focus is on developing treatments for cancer, aiming to improve efficacy and safety over existing therapies.

Recent filings

Filing Released Lang Actions
매출액또는손익구조30%(대규모법인은15%)이상변동
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a Korean company (Orum Therapeutics) announcing a significant change in financial results (revenue or profit/loss structure change of 30% or more). This is a standard disclosure requirement in the Korean market (DART system) when financial performance deviates significantly from the previous period. It provides key financial highlights and reasons for the variance, which fits the definition of an Earnings Release (ER) as it is an initial announcement of financial results before the final audited report.
2026-03-05 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of an upcoming Annual General Meeting (AGM) for '오름테라퓨틱' (Orum Therapeutics). It includes the date, location, and a detailed agenda of items to be voted on by shareholders, such as the approval of financial statements, director appointments, and amendments to the articles of incorporation. This document is a standard proxy solicitation/notice of meeting sent to shareholders to inform them of the meeting and request their participation/votes. Therefore, it falls under the Proxy Solicitation & Information Statement category.
2026-03-05 Korean
주주총회집중일개최사유신고
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing submitted by '오름테라퓨틱' (Orum Therapeutics) to report the reason for holding a General Meeting of Shareholders on a 'concentrated date' (a date when many companies hold their meetings). This is a specific regulatory disclosure requirement in the Korean market regarding shareholder meeting scheduling. Since it does not fit into the specific categories of AGM materials, proxy statements, or dividend announcements, and is a standard regulatory notification, it is best classified as a Regulatory Filing (RNS).
2026-03-05 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under Article 147 of the Capital Markets Act. This document details changes in share ownership, including the reporting of major shareholders and special related parties, and is classified as a Major Shareholding Notification (MRQ).
2026-02-19 Korean
[기재정정]주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea used to disclose significant changes in share ownership (often referred to as the 5% rule filing). It includes details on the reporter, special related parties, and the purpose of holding (influencing management). This falls under the 'Major Shareholding Notification' category.
2026-01-28 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details the shareholding status, changes in ownership due to capital increases and market transactions, and the purpose of holding (influencing management). This corresponds to the 'Major Shareholding Notification' category.
2026-01-23 Korean

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.